43.00
+0.25
(0.58%)
Jun 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 42.70 - 44.90 |
| 52 week | 8.00 - 65.16 |
| Open | 42.25 |
| Vol / Avg. | 288,237.00/192,232.00 |
| Mkt cap | 83.62M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 194.47M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Oct '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -27.11% | -32.13% |
| Return on average equity | -28.25% | -33.26% |
| Employees | 6 | - |
| Carbon Disclosure Rating | - | - |
Address
Department of Clinical Oncology City Hospital, Hucknall Road
NOTTINGHAM, ENG NG5 1PB
United Kingdom - Map
NOTTINGHAM, ENG NG5 1PB
United Kingdom - Map
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Scancell Holdings PLC is a United Kingdom-based company. The Company�s principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.
Officers and directors
| Lindy Gillian Durrant | Chief Executive Officer, Executive Director | |
| Richard Morley Goodfellow | Joint Chief Executive Officer, Executive Director, Commercial Director | |
| David Eric Evans | Non-Executive Chairman of the Board | |
| Peter Allen | Non-Executive Director | |
| Katherine Cornish-Bowden | Non-Executive Director | |
| Matthew Gerard Winston Frohn | Non-Executive Director | |
| Michael Rippon | Non-Executive Director |